Neurocrine Biosciences
Clinical trials sponsored by Neurocrine Biosciences, explained in plain language.
A biopharmaceutical company focused on neurological and endocrine disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for uncontrolled muscle movements: valbenazine trial targets stubborn TD symptoms Results expected Jan 2027 (estimated)
- New pill could tame involuntary twitching in mental health patients Results expected Feb 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
- New depression pill shows promise in Late-Stage trial Results expected Jul 2027 (estimated)
-
New hope for kids with rare sleep epilepsy?
Disease control CompletedThis study tested a drug called NBI-827104 in 24 children with a rare epilepsy that causes constant brain spikes during sleep. The drug is a calcium channel blocker given daily for 13 weeks. The main goal was to see if it reduces abnormal brain activity measured by EEG.
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 26, 2026 13:48 UTC
-
New depression pill shows promise in quick mood lift
Symptom relief CompletedThis phase 2 trial tested an experimental drug called NBI-1070770 in 73 adults with major depressive disorder. Participants took the drug or a placebo for 5 days to see if it could quickly improve depression symptoms. The study is already completed, and results will show whether …
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
New drug shows promise for controlling Huntington's chorea
Symptom relief CompletedThis Phase 3 study tested the long-term safety of valbenazine in 154 people with Huntington disease who have chorea (uncontrolled movements). Participants either continued from a previous study or joined new. The goal was to see if valbenazine is safe and helps control chorea ove…
Phase 3 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New hope for cerebral palsy: drug may tame involuntary movements
Symptom relief CompletedThis study tested a drug called valbenazine to see if it can reduce jerky, uncontrolled movements (chorea) in people with cerebral palsy. The trial included 86 children and adults whose medical condition was stable. Participants received either valbenazine or a placebo for 14 wee…
Phase 3 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
New hope for schizophrenia: valbenazine shows promise in phase 3 trial
Symptom relief CompletedThis study tested whether adding valbenazine to standard antipsychotic medication helps reduce schizophrenia symptoms in adults who did not respond well to treatment alone. Over 400 participants took either valbenazine or a placebo for 10 weeks. Researchers measured changes in sy…
Phase 3 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Valbenazine shows promise for easing involuntary movements in tardive dyskinesia
Symptom relief CompletedThis completed Phase 4 study tested valbenazine in 59 adults with tardive dyskinesia (involuntary muscle movements) caused by psychiatric medications. Participants had schizophrenia, bipolar disorder, or major depression. Over 24 weeks, researchers measured changes in quality of …
Phase 4 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC